A panel of Colby alumni and healthcare industry professionals convened for a Founders’ Forum event in Page Commons to discuss the strategic and operational challenges of building companies that aim to change disease diagnosis and treatment. The forum, “From Idea to Impact: Building Startups that Change How We Diagnose and Treat Disease,” brought together experts in finance, regulatory compliance, and clinical development to provide a practical overview of the necessary steps to turn a scientific concept into a commercial venture.
The panel consisted of three experienced professionals, each representing a major segment of the healthcare landscape: Graham Powis `90 `23, a Managing Partner at Brookline Capital Markets, whose expertise centers on public financing and capital markets advisory; Lori Zablow Salles P`27, who has held legal and compliance roles for major pharmaceutical and biotech firms, focusing on regulatory adherence; and Michael Paul, `87, CEO of MARAbio and co-founder of Lineagen, Inc., a company specializing in genetic diagnostic services.
The initial discussion focused on the core requirements for an early-stage company’s survival and growth. Paul, reflecting on his experience in growing a diagnostics company from a small team, emphasized the critical need for focus. He explained that a startup, faced with limited capital and resources, cannot afford to pursue multiple avenues simultaneously, stating that all efforts must be committed to solving one clear, specific problem. He further argued that, without a singular, defined objective, the company risks dissipating its scarce financial and human resources, hindering its ability to achieve key milestones necessary for subsequent funding rounds.
Salles added that organizational health is a requirement equal to the strength of the scientific idea. She noted that successful leadership necessitates humility, a willingness to actively listen to team members, and the ability to synthesize divergent viewpoints into a unified strategy. She explained that leaders must function as part of the team, and that finding the correct personnel “fit” within a small organization is necessary to avoid internal friction and resource depletion. Salles emphasized that team dynamics are highly sensitive in a startup environment, where every member’s performance is visible and critical to the company’s progress. She concluded that a forced fit in personnel leads quickly to internal conflict and reduced efficiency.
The speakers then addressed the scientific and regulatory obstacles that define the healthcare sector. Salles described the legal environment, noting that innovation is rigorously constrained by compliance requirements from bodies like the FDA and global regulatory entities. She explained that new treatments require not only initial approval but also careful and lengthy post-market monitoring to track and manage any potential long-term effects. She noted that this regulatory rigor is an unavoidable cost of operating within the medical field, demanding significant time and capital investment. Paul focused on scientific strategy, stating that the most successful ventures are those that validate a truly novel scientific mechanism, rather than developing small, incremental improvements to existing treatments. He stressed that once the science is proven, the company must clearly demonstrate how that discovery translates into a measurable clinical benefit for patients. This clinical validation is essential for gaining both regulatory approval and market adoption.
Powis provided a financial overview, detailing the “cyclical nature” of biotech funding. He observed that the market alternates between periods of high and low activity, which directly affects a young company’s strategic choices. He cited data that illustrated this fluctuation, noting that the number of Life Sciences Initial Public Offerings (IPOs) had dropped significantly in recent years compared to the high volume seen previously. Powis explained that a constrained IPO market often dictates that a company must pursue an early acquisition or strategic partnership to secure necessary capital, while an open market provides more control and flexibility regarding exit timing. The panelists advised that founders should prioritize maintaining strong business fundamentals and securing sufficient cash reserves over fixating on final exit strategies or market valuations. They noted that running out of money is the primary risk factor for any startup. Paul added that large pharmaceutical companies are often better positioned to handle expensive, late-stage efforts, such as Phase 3 clinical trials, making partnerships with them a common necessity for companies aiming to scale their impact globally due to the extensive resources and infrastructure required.
The event concluded with questions from students seeking career development and leadership guidance. One student asked the panelists for the most valuable advice they had received concerning leadership. Powis responded that the key was consistency. He explained that a leader must be a steady, reliable presence for the team, especially when the organization faces external pressures or internal crises. He further argued that this consistent behavior establishes trust and builds the necessary internal confidence for the team to continue executing its mission. Another question from the audience asked Paul about the most important non-financial value he gained from his career in healthcare entrepreneurship. Paul stated that the highest value derived from his work was the successful delivery of genetic diagnostic services to thousands of families, confirming that the mission of helping people served as the primary driver throughout the startup process.
~ Stephen Owusu Badu `27
Be First to Comment